|Day Low/High||86.90 / 87.01|
|52 Wk Low/High||19.62 / 87.01|
These stocks look poised to break out and trade higher from current levels.
Cramer wants to own FreshPet and prefers Pepsico over Dr Pepper Snapple.
Rarely does the market put the winning lottery ticket right in front of you, but today's winners were hiding in plain sight, Cramer says.
The perceived risk from macroeconomic issues — such as those in Europe — as well as changes in both interest rates and oil prices will make outright sales more attractive.
Valeant Pharmaceuticals is in a tentative deal to acquire the assets of Dendreon -- mostly its prostate-cancer vaccine Provenge and manufacturing facilities -- for $296 million in cash.
The hiring of a key Merck scientist and potential for combination cancer immunotherapy explain the recent rebound in Advaxis' stock price.
Big money can be made by buying and holding for the outsize gains.
Cramer likes BioMarin over Juno Therapeutics, Cypress Semiconductor over Micron Technology and Take-Two Interactive over Zynga.
It's earnings, earnings and more earnings for Cramer next week.
Startups launching an IPO or were acquired by a bigger fish contributed to a 28% increase in the valuation of these so called exit deals by venture-backed companies in 2014.
Following a week of awareness raising through phone calls, Twitter and a Loncar guest appearance on CNBC, the number of JPM breakout session webcasts has increased significantly.
The 2015 biotech stock predictions of TheStreet contributor David Sobek.
The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.
Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced that it will webcast its presentation at the 33 rd Annual J.
TheStreet's Adam Feuerstein lays down his predictions for the biotech industry for 2015.
Here's how investors can help fund the next cure for cancer: anti-CD47 antibody therapies.
Shares of Juno Therapeutics (JUNO) fell in early afternoon trading Tuesday as the stock sold off following three days of significant gains.
Shares of Juno Therapeutics (JUNO) soared to a new lifetime high of $56.50 on Monday after the biotech company filed an 8-K form.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.